MLRagent

Ad may be misleading if a page/spread lacks risk info or prominent locator reference

AI-verifiedwarningBinding lawRaised as a question — a person decides

Rule

When risk information (side effects and contraindications) is presented as a distinct part of an advertisement, the ad may be lacking in fair balance or otherwise misleading if any page or spread fails to include either that risk information or a prominent reference to its presence and location. This is a factor bearing on fair balance/misleadingness, not an independent, freestanding page-by-page mandate.

Check

For each page or spread, determine whether risk information appears or whether a reference to its presence and location appears and is prominent enough to be noticed relative to the surrounding promotional content; flag pages where neither is satisfied.

Escalate when

Escalate when it is unclear whether the risk information is presented as a "distinct part" of the ad (vs. integrated throughout), or when a locator reference exists but its prominence (size, placement, contrast) relative to surrounding promotional content is debatable.

Where this comes from

21 CFR 202.1(e)(7)(xii). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

…ons or the significant dosage considerations, when dosage recommendations are included in an advertisement, especially applicable to that selected class of patients. (xi) Fails to present on a page facing another page (or on another full page) of an advertisement on more than one page, information relating to side effects and contraindications when such information is in a distinct part of the advertisement. (xii) Fails to include on each page or spread of an advertisement the information relating to side effects and contraindications or a prominent reference to its presence and location when it is presented as a distinct part of an advertisement. (xiii) Contains information from published or unpublished reports or opinions falsely or misleadingly represented or suggested to be authentic or authoritative. (f)-(i) [Reserved] (j)(1) No advertisement concerning a particular prescription drug may be disseminated without prior approval by the Food and Drug Administration if: (i) The sponsor or the Food and Drug Administration has received information that has …
Document
21 CFR 202.1
Version
2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved
2026-09-21 from www.ecfr.gov
Fingerprint
a542640a872b3f2702d549e8…